Journal of Renal Nutrition
Volume 16, Issue 3 , Pages 253-258 , July 2006

Cinacalcet HCl: A Novel Treatment for Secondary Hyperparathyroidism Caused by Chronic Kidney Disease

  • Pablo Ureña Torres, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Pablo Ureña Torres, Service de Néphrologie et Dialyse, Clinique de l’Orangerie, 11 Boulevard Anatole France, 93300 Aubervilliers, France.

References 

  1. Young EW , Akiba T , Albert JM , et al.   Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS) . Am J Kidney Dis . 2004;44:34–38
  2. Ganesh SK , Stack AG , Levin NW , et al.   Association of elevated serum PO4, Ca PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients . J Am Soc Nephrol . 2001;12:2131–2138
  3. Gagné ER , Ureña P , Leite-Silva S , et al.   Short and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients . J Am Soc Nephrol . 1992;3:1008–1017
  4. Brown EM , Gamba G , Riccardi D , et al.   Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid . Nature . 1993;366:575–580
  5. Nemeth EF , Steffey ME , Hammerland LG , et al.   Calcimimetics with potent and selective activity on the parathyroid calcium receptor . Proc Natl Acad Sci U S A . 1998;95:4040–4045
  6. Slatopolsky E , Gradowska L , Kashemsant C , et al.   The control of phosphate excretion in uremia . J Clin Invest . 1966;45:672–677
  7. Shigematsu T , Kazama JJ , Yamashita T , et al.   Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency . Am J Kidney Dis . 2004;44:250–256
  8. Ureña P , Kubrusly M , Mannstadt M , et al.   The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure . Kidney Int . 1994;45:605–611
  9. Silver J , Kilav R , Naveh-Many T . Mechanisms of secondary hyperparathyroidism . Am J Physiol Renal Physiol . 2002;283:F367–F376
  10. Fukuda N , Tanaka H , Tominaga Y , et al.   Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients . J Clin Invest . 1993;92:1436–1443
  11. Tominaga Y , Tanaka Y , Sato K , et al.   Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism . Semin Surg Oncol . 1997;13:78–86
  12. Gogusev J , Duchambon P , Hory B , et al.   Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism . Kidney Int . 1997;51:328–336
  13. Kifor O , Moore FD , Wang P , et al.   Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism . J Clin Endocrinol Metab . 1996;81:1598–1606
  14. Tominaga Y , Kohara S , Namii Y , et al.   Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism . World J Surg . 1996;20:744–750
  15. Tominaga Y , Sato K , Tanaka Y , et al.   Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure . Clin Nephrol . 1995;44(suppl 1):S42–S47
  16. Arnold A , Brown M , Ureña P , et al.   Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia . J Clin Invest . 1995;95:2047–2054
  17. Massry SG , Smogorzewski M . Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia . Semin Nephrol . 1994;14:219–231
  18. Rostand SG , Drueke TB . Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure . Kidney Int . 1999;56:383–392
  19. Amann K , Ritz E . Cardiac disease in chronic uremia (Pathophysiology) . Adv Ren Replace Ther . 1997;4:212–224
  20. Amann K , Tornig J , Flechtenmacher C , et al.   Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia (Evidence for a permissive action of PTH) . Nephrol Dial Transplant . 1995;10:2043–2048
  21. Kosch M , Hausberg M , Vormbrock K , et al.   Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy . Cardiovasc Res . 2000;47:813–818
  22. London GM , Guerin AP , Marchais SJ , et al.   Arterial media calcification in end-stage renal disease (Impact on all-cause and cardiovascular mortality) . Nephrol Dial Transplant . 2003;18:1731–1740
  23. Rodriguez M , Nemeth E , Martin D . The calcium-sensing receptor (A key factor in the pathogenesis of secondary hyperparathyroidism) . Am J Physiol Renal Physiol . 2005;288:F253–F264
  24. Ramirez JA , Goodman WG , Gornbein J , et al.   Direct in vivo comparison of calcium regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism . J Clin Endocrinol Metab . 1993;76:1489–1494
  25. Kessler A , Faure H , Petrel C , et al.   N(2)-benzyl-N(1)-(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues (Development of calindol as a new calcimimetic acting at the calcium sensing receptor) . Bioorg Med Chem Lett . 2004;14:3345–3349
  26. Petrel C , Kessler A , Dauban P , et al.   Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain . J Biol Chem . 2004;279:18990–18997
  27. Antonsen JE , Sherrard DJ , Andress DL . A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication . Kidney Int . 1998;53:223–227
  28. Goodman WG , Frazao JM , Goodkin DA , et al.   A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism . Kidney Int . 2000;58:436–445
  29. Mimpara (Cinacalcet) SPC . Breda, the Netherlands: Amgen; 2004;
  30. Sensipar (Cinacalcet HCl) Prescribing Information . Breda, the Netherlands: Amgen; 2004;
  31. Coburn J , Barri Y , Turner S , et al.   Single doses of the calcimimetic AMG-073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism . J Am Soc Nephrol . 2000;11:573A
  32. Ureña P , Basile C , Grateau G , et al.   Short-term effects of parathyroidectomy on plasma biochemistry in chronic uremia (A prospective study) . Kidney Int . 1989;36:120–126
  33. VanAbel M , Hoederop JGJ , VanLeeuwen JPTM . Down-regulation of Ca2+ transporters in kidney and duodenum by the calcimimetic compound NPS R-467 . J Am Soc Nephrol . 2003;14: SA-P073, (abstr)
  34. Drueke T , Cunningham J , Goodman W , et al.   Short-term treatment of secondary hyperparathyroidism (SHTP) with the calcimimetic agent AMG 073 . J Am Soc Nephrol . 2001;12:764A
  35. Block GA , Martin KJ , deFrancisco AL , et al.   Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis . N Engl J Med . 2004;350:1516–1525
  36. Urena P , Legoupil N , deVernejoul MC , et al.   Sustained control of uraemic secondary hyperparathyroidism (SHPT) after three years of treatment with the calcimimetic cinacalcet HCL (A single centre experience) . 2003; Poster presented at the 40th ERA-EDTA World Congress of Nephrology, Berlin
  37. Quarles LD , Sherrard DJ , Adler S , et al.   The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease . J Am Soc Nephrol . 2003;14:575–583
  38. Lindberg JS , Moe SM , Goodman WG , et al.   The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism . Kidney Int . 2003;63:248–254
  39. Mittman N , Finkelstein F , Culleton B , et al.   Cinacalcet HCl (Sensipar) for the management of secondary hyperparathyroidism in study patients receiving peritoneal dialysis . J Am Soc Nephrol . 2004;15:280A; (abstr)
  40. Bushinsky DA . Cinacalcet HCl in secondary hyperparathyroidism . Official Evening Symposium (ASN 2004) . St. Louis, Missouri: American Society of Nephrology; 2004; October 27 to November 1
  41. Moe SM , Chertow GM , Coburn JW , et al.   Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl . Kidney Int . 2005;67:760–771
  42. Moe SM , Cunningham J , Bommer J , et al.   Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl . Nephrol Dial Transplant . 2005;20:2186–2193
  43. Cunningham J , Chertow G . Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism . Kidney Int . 2005;68:1793–1800
  44. Evenepoel P , Claes K , Kuypers D , et al.   Natural history of parathyroid function and calcium metabolism after kidney transplantation (A single-centre study) . Nephrol Dial Transplant . 2004;19:1281–1287
  45. Kruse AE , Eisenberger U , Frey FJ , et al.   The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism . Nephrol Dial Transplant . 2005;20:1311–1314
  46. Serra AL , Schwarz AA , Wick FH , et al.   Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism . Nephrol Dial Transplant . 2005;20:1315–1319
  47. Collins MT , Skarulis MC , Bilizkian JP , et al.   Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent . J Clin Endocrinol Metab . 1998;83:1080–1082
  48. Rubin MR , Sliney J , Silverberg SJ , et al.   Clinical course of 10 patients with inoperable parathyroid carcinoma treated with the calcimimetic cinacalcet HCl . J Bone Miner Res . 2004;19:S103; (abstr F497)

PII: S1051-2276(06)00091-4

doi: 10.1053/j.jrn.2006.04.010

Journal of Renal Nutrition
Volume 16, Issue 3 , Pages 253-258 , July 2006

Article Tools